Kornimate/medical-research-clean huggingface dataset:
low level laser therapy and interferential current in osteoarthritis

Conditions: Osteoarthritis

Summary: this study aims to evaluate the effectiveness of the low level laser therapy and interferential current in 168 patients with knee osteoarthritis

interventional

Eligibility criteria:
inclusion criteria: * history of osteoarthritis of the knee characterized by pain of mild or moderate intensity * radiographic evidence of grade 2 or 3 osteoarthritis based on the kellgren and lawrence radiographic entry criteria * patients with knee osteoarthritis (s) according to the acr criteria * vas 3 to 8 * 5 to 12 lequesne * no complaint of pain in other joints of the lower limbs * without neurological and cognitive disorders * no loss of sensation in the lower limbs * no surgery on the knee (s) in the last 6 months * pain symptoms for at least 6 months * no infiltrations (s) knee (s) in the last 4 weeks * no use of analgesics 4 hours before treatment exclusion criteria: * individuals younger than 18 and older than 80 years * complaints from other diseases of the lower limbs, knee prosthesis and / or hip joint instabilities and / or surgery in lower limbs, heart disease, uncontrolled hypertension and diabetes, coagulation disorders in anticoagulant therapy, pregnant women, fibromyalgia and individuals who can not perform isokinetic test who have difficulty performing the tug, and those that are experiencing abnormal sensitivity to algometry
anatomic endoscopic prostate enucleation and bicep classification

Conditions: Bladder Injury; Prostate Hyperplasia

Summary: the bladder injury classification system for endoscopic procedure (bicep) is designed to provide a systematic framework for categorizing bladder injuries that occur during endoscopic procedures. by standardizing the classification of these injuries, bicep promotes a more consistent approach to diagnosis, management, and prevention across different urologic interventions. this study aims to validate and implement the bicep system during morcellation. this study will: validate bicep by using real-life clinical scenarios to ensure its applicability and effectiveness. assess the incidence and types of bladder injuries during morcellation, using the bicep categorization to standardize injury reporting and enhance treatment protocols.

insufficient knowledge exists about bladder injuries during morcellation, as the existing literature primarily consists of isolated case reports. the bladder injury classification system for endoscopic procedures (bicep) aims to standardize the reporting and management of bladder injuries during endoscopic surgeries. this study proposes an external validation of the bicep system through an international, multicenter, prospective observational study. the objectives of this study are fourfold: validate the newly developed bicep classification system with real-life clinical scenarios to ensure its applicability and effectiveness. evaluate the incidence and types of bladder injuries during morcellation using the bicep framework to standardize injury reporting and enhance treatment protocols. assess the robustness of bicep across different departments. facilitate the adoption of bicep as a global standard for classifying bladder injuries in endoscopic surgery. through this study, the validity of bicep will be confirmed and the bladder injuries occurring during morcellation after aeep will be examined.

Eligibility criteria:
inclusion criteria: * patients aged ≥40 * asa (american society of anesthesiologists) score ≤3 * estimated weight on ultrasound (usg) ≥40 grams for prostate weight * patients undergoing holmium laser enucleation of the prostate (holep) or transurethral resection of the prostate (turp) surgery. exclusion criteria: * patients with neurological disorders that may affect bladder function, such as cerebrovascular stroke or parkinson's disease. * patients with active urinary tract infection. * patients diagnosed with bladder cancer within the last 2 years. * patients with prostate cancer. * patients who have undergone previous prostate surgery.

Keywords: bicep classification anatomic endoscopic enucleation of prostate bladder injury holep bilep thuflep
burke-hocoma efficiency study

Conditions: Hemiparesis; Hemiplegia

Summary: the armeospring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. the investigators hypothesize that 3 days of training for 6 weeks with the hocoma armeo spring device will be efficient and more effective than one on one armeospring therapy.

in the proposed study, 20 stable subacute and chronic stroke patients will be placed in two groups: 2:1 treatment for 3 weeks (2 patients on 2 robots with one therapist; 60 minutes on robot) then 1 on 1 intervention with the therapist (60 minutes of hocoma armeo spring robotic training) or visa versa. patients will be assessed using robotic kinematics and standardized occupational therapy motor assessments. the extreme precision afforded by robotic physical rehabilitation therapies makes them an appealing and growing field in rehabilitation. determining efficiency of new technologies, while maintaining the highest quality of care, is of priority in the medical field at this time. devices such as the armeospring could lead to reduced disability, thereby increasing function and improving quality of life in patients experiencing neurological illness or injury. the armeospring has potential to decrease cost for both the provider and patient over time while providing more engaging, evidence-based therapy.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral upper extremity hemiparesis/hemiplegia * upper extremity fugl-meyer assessment score between 7-60 (neither hemiplegic nor fully recovered motor function of the shoulder, elbow, wrist) exclusion criteria: * inability to follow 1-2 step commands * fixed joint contracture * unable to tolerate repetitious movement exhibited by pain greater than 5 on likert scale * any device dependent restrictions
oxidized cellulose hemostasis evaluation

Conditions: Intra-operative Bleeding

Summary: the purpose of this study is to evaluate the safety and effectiveness of traumastem to help stop bleeding in participants undergoing open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery as compared to surgicel® original (surgicel; in some countries marketed as tabotamp®)


Eligibility criteria:
inclusion criteria at screening: 1. participants and/or legal representative has/have provided signed informed consent. an assent form should be signed by participants less than 18 years of age, if possible; 2. participants undergoing planned (non-emergency) open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery; 3. participants of childbearing potential present with a negative serum pregnancy test, and agree to employ adequate birth control measures for the duration of the study. acceptable contraception methods are restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices or licensed hormonal products; 4. participants are willing and able to comply with the requirements of the clinical investigation plan (cip). inclusion criteria intra-operative: 5. soft tissue, vascular/anastomotic or parenchymal bleeding is present after primary surgical hemostasis has been achieved. the tbs is defined as intra-operative bleeding where conventional methods for achieving hemostasis are ineffective (based on the type of tissue) or impractical (based on the location) and where treatment with topical hemostatic adjuncts such as traumastem is deemed appropriate for use. exclusion criteria: 1. emergency surgery; 2. transplantation surgery; 3. minimally invasive surgery; 4. neurological and ophthalmological surgery; 5. major arterial bleeding at the target bleeding site (tbs); 6. major intra-operative complications that require resuscitation or deviation from the planned surgical procedure; 7. severe local inflammation at the operating field; 8. any prior radiation therapy to the operating field; 9. known severe congenital or acquired immunodeficiency (eg, human immunodeficiency virus \[hiv\] infection or long-term \[\> 3 months\] treatment with immunosuppressive drugs); 10. known hypersensitivity to components of the investigational device; 11. participant is pregnant or lactating at the time of enrollment or becomes pregnant prior to the planned surgery. if the participant becomes pregnant during the 30 days following treatment exposure, attempts will be made to follow her through completion of the pregnancy. the investigator will record a narrative description of the course of the pregnancy and its outcome; 12. participant has a clinically significant medical, psychiatric, or cognitive illness, or drug/alcohol abuse that, in the opinion of the investigator, would affect participant's safety or compliance; 13. participant has participated in another clinical study involving an investigational device/drug within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational device/drug during the course of this study.
effect of different doses of sar110894 on cognition in patients with mild to moderate alzheimer's disease on donepezil

Conditions: Dementia Alzheimer's Type

Summary: primary objective: - to demonstrate the efficacy of at least one dose of sar110894 (h3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate alzheimer's disease (ad) while on stable donepezil therapy secondary objectives: * to explore the effect of sar110894 on functional impairment, global clinical status and behavioral disturbances; * to assess the safety/tolerability of sar110894; * to assess pharmacokinetic (pk) of sar110894 and concentrations of donepezil; * to explore caregiver time consumption and distress changes.

the total study duration for each patient is approximatively 36 - 38 weeks broken down as follows: * screening period: up to 4 weeks, * treatment period: 24 weeks, * follow-up period: 10 weeks.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of alzheimer's disease (ad) (cannot be dementia from strokes or other causes). * patient is on stable and well-tolerated donepezil treatment at a dose of either 5 or 10 mg daily for at least 3 months prior to screening visit. exclusion criteria: * age \<55 years old. * psychotic features, agitation, or behavioral problems within the last 3 months. * patients unable to comply with ophthalmologic monitoring. * lack of consistent and reliable caregiver. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
protocol phototherapy treatment for fibromyalgia and temporomandibular joint dysfunction

Conditions: Pain; Quality of Life

Summary: temporomandibular joint dysfunction is described as a multifactorial disease and can be directly linked to other diseases, being of structural factors of the stomatognathic system or not, such as fibromyalgia. studies show the interconnection of temporomandibular dysfunctions with fibromyalgia. thus, this project aims to evaluate the effect of phototherapy on fibromiálgicos patients with temporomandibular dysfunction this is a randomized, controlled and double-blind, with the intention to treat. in this way the sample of 61 patients with fibromyalgia, temporomandibular joint dysfunction associated with ages between 35 to 58 years, females who are selected after the inclusion/exclusion criteria, will be randomly distributed in homogeneous groups and the placebo group (p), phototherapy (ft) group, group of physical activity (a) aerobic and aerobic physical activity + phototherapy group (ft + a). will be used as a means of analysis before and after interventions the following parameters: pain: clinical evaluation, evaluation of pain by visual analog scale of pain (eva), mcgill pain questionnarire and pressure algometria. still we will evaluate the dosage of serotonin, indirectly, by saliva. quality of life: own illness as questionnaires fiq (fibromyalgia impact questionnaire), medical outcomes study 36-item short-form health survey sf-36 and also will assess the quality of sleep, with polysomnography. the treatments will total in 10 sessions held twice a week, and the ft and ft + groups to receive phototherapy enforcement will be used a portable cluster 9 diodes, where will be delivered 39.3 joules in tender points of fibromyalgia and tmj, groups and ft + to carry out aerobic activity in 75% of your mhr for 50 min and the p group will receive the application of phototherapy of 0 joules (ie, the equipment does not emit any power). statistical analysis will be compared using the t test intra-group-student, one-tail and paired and can be used the kruskal-wallis test, the statistical analysis of significance 0.05 for both tests.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of fibromyalgia according to the criteria of the american college of rheumatology; * clinical diagnosis of tmd by the rdc questionnaire (annex i); * cognitive level enough to understand the procedures and follow the guidelines that will be passed; * people who use drugs corresponding to fibromyalgia (fm), antidepressant; * class i of angle * consent to participate in the study and sign the consent form post information. exclusion criteria: * with psychiatric disorders; * cognitive changes; * people who perform some exercise; * people who carry out orthodontic treatment; * systemic diseases; * persons under the age of 35 and more than 58 years.

Keywords: phototherapy laser fibromyalgia dtm/ tmd pain
transobturator sling compared with single-incision mini-sling for the treatment of stress urinary incontinence

Conditions: Injury Due to Sling-shot

Summary: 1. objective: to determine the efficacy and safety of a single-incision mini-sling compared with a transobturator midurethral sling for stress urinary incontinence (sui) treatment. 2. methods: this prospective single-center randomized controlled trial will involve 100 women with a diagnosis of sui. primary outcomes were the objective and subjective cure rates, defined as negative cough stress and pad tests, and satisfaction rates. quality of life assessed by the incontinence quality of life questionnaire and the urogenital distress inventory short form, operation time, complications, and reoperation rates were also recorded. the efficacy was analyzed using a noninferiority test with a margin of 15%. for the noninferiority test, a p value \>.05 rejects the noninferiority hypothesis of the mini-sling.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * clinical and urodynamic diagnosis of stress urinary incontinence * absence of associated neurological diseases * no clinically significant detrusor instability (ie, to determine which symptoms are proportionally more significant for patient incontinence efforts) exclusion criteria: * urodynamic changes suggesting a reduction in bladder capacity, bladder compliance or suggestive of bladder outlet obstruction * coagulopathies * pregnancy * history of sensitivity to foreign body * acute urinary tract infection * sequelae of high exposure to ionizing radiation * use of drugs that can result in high and / or risk of significant postoperative complications surgical risk, including any drug that interferes with blood clotting * anesthetic contraindication to the procedure * vulvovaginitis: presence of vaginal discharge with laboratory proven infection

Keywords: stress incontinence transobturator sling single-incision mini-sling
co-administration study in patients with elevated cholesterol and coronary heart disease (0653-803)

Conditions: Hypercholesterolemia; Coronary Disease

Summary: the purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.

the duration of treatment is 10 weeks.

Eligibility criteria:
inclusion criteria: * patients with elevated cholesterol and coronary heart disease exclusion criteria: * patients who have cholesterol levels within normal ranges as identified by the study

Keywords: elevated cholesterol
long-term ovarian fertility in patients treated for lymphoma.

Conditions: Lymphoma, Follicular

Summary: this is an observational, single-center, longitudinal cohort study. in order to evaluate the gonadotoxicity of chemotherapy, an amh monitoring was initiated in 2006 in our fertility observatory in young patients with lymphoma before, during and after chemotherapy. this study is part of the project "she will get better and then want a child" and is supported by the ars hauts de france (n° dos/sdes/ar/fir/2019/282). our first study published in 2010 shows that amh decreases sharply during chemotherapy, regardless of the chemotherapy protocol. at the end of chemotherapy, amh recovery profiles differ according to the protocol received. this follow-up is therefore essential in order to adapt our practices and our preservation strategies, particularly to the type of chemotherapy. patients are primarily concerned about their chances of subsequent pregnancy, and there is little evidence in the literature about the impact of chemotherapy on ovarian reserve and long-term fertility. the fisrt objective of our study is to evaluate, at distance from chemotherapy, the evolution of ovarian function in patients treated for lymphoma by evaluating follicular reserve parameters (amh and antral follicle count) at 5 and 10 years after the end of chemotherapy compared with the initial workup performed before chemotherapy and the workup performed at 12 months after the end of chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with a history of lymphoma treated with chemotherapy * followed in the fertility observatory of the jeanne de flandre hospital at the university hospital of lille (project "she will heal and then want a child"), who are at least at 5 years since the end of chemotherapy * patients having been informed and having given their written consent to participate in the study. * beneficiary of a social security system. exclusion criteria: * patient not followed in the fertility observatory. * inability of the patient to undergo the medical follow-up of the trial for geographical, social or psychological reasons. * patient opposed to her participation in the study. * patient under guardianship or curatorship.

Keywords: ovarian reserve chemotherapy, antimüllerian hormone, lymphoma, fertility, follicle antimüllerian hormone, lymphoma, fertility, follicle lymphoma follicle
the expression of cd24 "do-not-eat-me" signal in cholangiocarcinoma

Conditions: Cholangiocarcinoma

Summary: the investigators found an inverse relationship between cd24 and mir-122 levels. then the investigators found that cd24 that goes up with mir-122 down makes macrophages unable to engulf the tumor cells. all this in mice. the investigators are interested in confirming this result in humans. details of the preliminary results are attached to the submission of the research documents. the investigators will compare cholangiocarcinoma tumors with other solid tumors, including liver tissue. the need to deepen understanding the investigators will also make a comparison between cancerous tissue and "normal" tissue adjacent to the tumor.

the investigators will collect samples from the tissue bank. all materials will be kept in refrigerators at minus 80, except for the sections of the paraffin blocks at room temperature. the source of some of the biological samples and the information accompanying them in this study is midgem - the israeli repository for biological samples for research. midgem is a non-profit association that operates within the ministry of health as an infrastructure for the promotion of bioresearch - medical and industrial in israel. the donors to midgem are patients with malignant diseases, non-malignant diseases as well as healthy volunteers. in midgem, residues are collected from tissues already removed during surgery/taking a biopsy and/or samples from blood/saliva/urine/other body fluids donations and the accompanying medical information required for use in legally approved studies.there is no risk to the donors as a result of the donation of the samples and information and their use, since the donation is transferred to midgem only after it has been ascertained beyond any doubt that the ability of the diagnosis and/or treatment of the donors will not be harmed. all the information transferred to the researchers is coded, in such a way that the investigators do not allow the identification of the donors' details. since the donors to midgem have signed a consent form for the collection and storage of samples and information for use in any legally approved study, the investigators request an exemption from signing a dedicated informed consent form for this study. the samples and information transferred to this study are donated in accordance with what is detailed in the inclusion criteria for the experiment.

Eligibility criteria:
inclusion criteria: \* donors with cholangiocarcinoma samples exclusion criteria: \* donors who do not have cholangiocarcinoma samples

Keywords: cd24 human liver cancer mir122
buttonhole versus step ladder cannulation in high dose hemodialysis

Conditions: Renal Failure

Summary: the purpose of the pilot study is to determine: 1) will patients agree to be randomized to two different methods of putting needles in their arteriovenous fistula and, 2) if we can adequately coordinate all of the sites to get useful multicentre trial data

to determine the feasibility of 1) randomizing patients to step-ladder versus buttonhole cannulation techniques, and 2) coordinating the multiple canadian sites that are required for the definitive study. secondary objectives: to determine 1) if buttonhole cannulation, compared to step-ladder cannulation is associated with reduced training time for high dose home hemodialysis patients, 2) if buttonhole cannulation, compared to step-ladder cannulation is associated with reduced overall cost, 3) if buttonhole cannulation, compared to step-ladder cannulation is associated with reduced complications (infection - local and systemic, radiologic/surgical interventions, re-trains for needle insertion difficulties, hematoma formation, aneurysm formation, missed insertions), and 4) if buttonhole cannulation, compared to step-ladder cannulation is associated with reduced patient discomfort with needling for intensive home hemodialysis patients

Eligibility criteria:
inclusion criteria: 1. adult patients \> 18 years old, 2. training for home hemodialysis 3. able to give informed consent, 4. arteriovenous fistula 5. life expectancy of greater than 12 months. exclusion criteria: 1. potential to be lost from the program within 12 months of training (planned living donor transplant, transfer to peritoneal dialysis (pd) or move from training centre catchment area), 2. allergy to mupirocin, 3. short segments or aneurysms within the arteriovenous fistula (avf) that the attending nephrologist believes require buttonhole cannulation., 4. mechanical heart valves, 5. patients who require intradermal lidocaine for needle insertion -

Keywords: renal failure hemodialysis canulation technique training time cost patient discomfort with cannulation technique